Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Renal denervation shown safe and effective in pivotal trial

Key clinical point: Renal denervation may help fill the major unmet need for new treatments for hypertension.

Major finding: Renal denervation resulted in a 4–mm Hg greater reduction in 24-hour ambulatory SBP than a sham procedure at 3 months follow-up in patients with untreated hypertension.

Study details: SPYRAL HTN-OFF MED was a prospective randomized trial including 331 patients with untreated hypertension who underwent renal denervation or a sham procedure and were followed off-medication for 3 months.

Disclosures: The study was sponsored by Medtronic. The presenter reported serving as a consultant to that company and Abbott, Amgen, Astra, Boehringer-Ingelheim, Cytokinetics, Novartis, ReCor, Servier, and Vifor.


Boehm M. ACC 2020, Abstract 406-15.